Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX + regorafenib + PD-1 antibody for first-line HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2000033070Phase 2Recruiting
- Sponsor
- Shanghai East Hospital
- Start
- May 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, oxaliplatin, regorafenib and PD-1 Monoclonal Antibody in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Shanghai East Hospital. Primary endpoint: Objective response rate. Started May 2020; status: recruiting.
02
Drugs
capecitabineoxaliplatinregorafenibPD-1 Monoclonal Antibody
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2000033070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033070.